Made Scientific Partners with Basilard BioTech to Advance Nanomechanical Gene Delivery Platform for Cell Therapies
Key Insights
Made Scientific (search) and Basilard BioTech (search) announced a strategic collaboration to accelerate development of Celletto™ (search), a nanomechanical gene delivery platform that uses nanoneedles for direct nuclear transport.
The Celletto™ (search) technology addresses limitations of viral vectors and conventional non-viral methods by maintaining superior cell viability while achieving high gene transfer efficiency.
The partnership will leverage Made Scientific (search)'s GMP manufacturing facility in Princeton, NJ to validate and scale the platform for T cell and iPSC therapies.
Made Scientific (search), a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Basilard BioTech (search), a Southern California biotechnology company, announced a strategic collaboration on September 15, 2025, to accelerate the development and translation of Basilard BioTech's nanomechanical gene delivery platform, Celletto™ (search). The partnership aims to advance ex vivo gene delivery capabilities for T cell and induced pluripotent stem cell (iPSC) therapies.
Revolutionary Nanomechanical Gene Delivery Technology
Celletto™ (search) represents a disruptive nanomechanical gene delivery technology designed to address long-standing limitations of both viral vectors and conventional non-viral methods. The platform creates a controlled, transient disruption to the cell membrane using nanoneedles to directly transport nucleic acids or any construct into the nucleus of any cell type.
Unlike viral systems that are costly, complex, and carry insertional mutagenesis risks, or chemical/electroporation approaches that compromise viability, Celletto™ (search) delivers several key advantages. The technology maintains superior cell viability by preserving the functional integrity of sensitive cell types, including T cells (search) and iPSCs (search), enabling higher recovery rates and robust expansion.
The platform achieves high gene transfer efficiency with reliable and reproducible delivery of genetic payloads across diverse constructs, including large plasmids and gene-editing components. Engineered on silicon wafers as a modular platform, Celletto™ (search) is adaptable for both small-scale research use and GMP-compliant large-scale manufacturing, offering a clear path from bench to clinic.
Manufacturing Partnership and Scalability
Under the agreement, Basilard BioTech (search) will leverage Made Scientific (search)'s Center of Excellence for Process and Analytical Development and state-of-the-art GMP manufacturing facility in Princeton, NJ, to validate and scale the Celletto™ (search) platform across T cell, iPSC processes, and other cell substrates in the future.
By eliminating dependence on viral vectors, Celletto™ (search) can significantly shorten production timelines and reduce costs, helping to make advanced therapies more accessible. The technology's scalability and flexibility provide a clear pathway for commercial manufacturing.
Leadership Perspectives
"We look forward to collaborating with Made Scientific (search) to demonstrate the transformative, and disruptive potential of Celletto™ (search)," said Brynley Lee, Founder, President and CEO of Basilard BioTech (search). "Our goal is to create a gene delivery solution that works seamlessly with all cell types, preserves cell health, drives reproducible gene transfer, and scales seamlessly from research to GMP production, ultimately accelerating the path to safer, more effective therapies."
Syed T. Husain, Chairman & CEO of Made Scientific (search), emphasized the partnership's potential impact: "Our partnership with Basilard BioTech (search) opens up an exceptional pathway to bring next-generation gene delivery into mainstream manufacturing. By pairing Basilard's Celletto™ (search) platform with Made Scientific's end-to-end clinical and commercial CDMO services, we can provide biotech innovators with a more scalable, efficient, and commercially viable solution for advancing transformative T cell and iPSC therapies."
Timeline and Next Steps
On-site installation, training, and execution of joint studies is currently underway, with initial data readouts expected by the end of Q3 2025. The companies plan to publish results and present findings at upcoming industry conferences.
Made Scientific (search) operates from two U.S.-based manufacturing facilities and combines the agility of a specialist CDMO with the global expertise and resources of GC Corporation (search) of South Korea. Basilard BioTech (search)'s Celletto™ (search) platform represents a second-generation nanomechanical gene delivery technology designed to overcome the inefficiencies, costs, and safety concerns of existing viral and non-viral systems.